MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, at 1:55 p.m. ET.
To access the live webcast of MyoKardia’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461). Mavacamten is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in Phase 1 clinical studies of HCM patients. In April 2016, the FDA granted Orphan Drug Designation for mavacamten for the treatment of symptomatic oHCM, a subset of HCM. MyoKardia is currently studying mavacamten in PIONEER-HCM. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 [email protected] Media Contact: Steven Cooper Edelman 415-486-3264 [email protected]
